KALV KalVista Pharmaceuticals Inc

Price (delayed)

$26.95

Market cap

$1.43B

P/E Ratio

N/A

Dividend/share

N/A

EPS

N/A

Enterprise value

$1.37B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: N/A

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary ...

Highlights
KALV's quick ratio is down by 8% since the previous quarter

Key stats

What are the main financial stats of KALV

KALV stock price

How has the KalVista Pharmaceuticals stock price performed over time
Intraday
0%
1 week
0.67%
1 month
1.09%
1 year
99.04%
YTD
66.87%
QTD
33.88%

Financial performance

How have KalVista Pharmaceuticals's revenue and profit performed over time
Revenue
N/A
Gross profit
N/A
Operating income
N/A
Net income
N/A
Gross margin
N/A
Net margin
N/A

Price vs fundamentals

How does KALV's price correlate with its fundamentals

Growth

What is KalVista Pharmaceuticals's growth rate over time

Valuation

What is KalVista Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Efficiency

How efficient is KalVista Pharmaceuticals business performance

Dividends

What is KALV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KALV.

Financial health

How did KalVista Pharmaceuticals financials performed over time
KALV's total assets is 6% lower than its total liabilities
KALV's quick ratio is down by 8% since the previous quarter
KalVista Pharmaceuticals's current ratio has decreased by 7% QoQ
The debt to equity has soared by 86% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.